Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 3GS; Glucoronylglucosaminoglycan sulphate; KRX-101; Sulodexide Gelcaps; Sulonex; Vessel

Latest Information Update: 05 Oct 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alfa Wassermann SpA
  • Developer Alfa Wassermann SpA; Keryx Biopharmaceuticals
  • Class Antihyperlipidaemics; Antithrombotics; Glycosaminoglycans
  • Mechanism of Action Glycosaminoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombosis; Vascular disorders
  • Phase III Venous insufficiency; Venous thromboembolism
  • Discontinued Diabetic nephropathies; Glomerulonephritis; Kidney disorders; Pulmonary fibrosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Dec 2017 Alfa Wassermann Tunisia in collaboration with Poseidon CRO plans the AWAOMI2 phase III trial for Peripheral Arterial Obstructive Disease in Tunisia , (NCT03370705)
  • 19 Sep 2016 Phase-III clinical trials in Venous insufficiency in Poland (PO) (EudraCT2016-000783-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top